|
|
Post by liane on Apr 21, 2017 15:48:21 GMT -5
|
|
|
|
Post by mnkdfann on Apr 21, 2017 15:53:46 GMT -5
The worst part for me is to hear the apathy from the average diabetic with regard to their own health. It's not just a doctor prescribing problem, the patients can be a barrier as well. I always cringe when I see tweets from people about so-called Afrezza challenges. Take Afrezza, then see how much sugar / how many carbs you can stuff down your gullet. Or when people say things like what a great promotional event it would be at an ADA meeting to have diabetic kids on stage gorge on sugary drinks and donuts and then show how Afrezza keeps their numbers under control. Even non-diabetics should be discouraged from such activities. |
|
|
|
Post by dreamboatcruise on Apr 21, 2017 16:18:47 GMT -5
It's depressing.... I still dont understand how MNKD is selling this.. They are in Valencia (Los Angeles) and Danbury. Even if they hire just 50 people, and talk to Drs only in LA AND do one-on-one with every patient from Dr-->prescription-->Insurance-->Drug delivery, I'm sure they could easily get 200 patients a week - isn't it? And, that will cost less than now too - IMO. The plan they are falling, ROI is just not there. They are doing this again and again and again. I really dont understand. May be they have a plan? 3 years, and still we are in square 1? One thing you don't understand is that pharma sales reps don't sell directly to patients. It's a highly regulated industry. |
|
|
|
Post by tingtongtung on Apr 21, 2017 16:59:10 GMT -5
It's depressing.... I still dont understand how MNKD is selling this.. They are in Valencia (Los Angeles) and Danbury. Even if they hire just 50 people, and talk to Drs only in LA AND do one-on-one with every patient from Dr-->prescription-->Insurance-->Drug delivery, I'm sure they could easily get 200 patients a week - isn't it? And, that will cost less than now too - IMO. The plan they are falling, ROI is just not there. They are doing this again and again and again. I really dont understand. May be they have a plan? 3 years, and still we are in square 1? One thing you don't understand is that pharma sales reps don't sell directly to patients. It's a highly regulated industry. Didn't mean it literally.. What I meant was not go to patient's house and sell it. Work with a small number of Drs (after looking at the trend from the last 2-3 years) in a very limited area, and when a patient gets a prescription, work with them to get insurance cleared, and then ship them the product directly (which Mike said he is planning to do now?). No idea this is legal or not. I'm just expressing my thoughts. Why are these guys repeating the same thing forever? They could try to educate Drs all over the country slowly provided they have 2/3 years of cash. When they barely have a few months of cash, why look at the whole country? Work in a city/county/zipcode. 9% of US population has diabetes. LA population is 4 million ==> 360,000 diabetes people. Assuming 1% are candidates for Afrezza == 36,000. If we could get 36,000 scripts from just LA, wouldn't it be awesome? Hypothetical. Again, I'm not saying MNKD should do exactly this.. Of course, I'm not in this industry, and I know next to nothing in this industry. I just invested in this looking at the drug. I don't know everything about everything. |
|
|
|
Post by peppy on Apr 21, 2017 17:11:29 GMT -5
One thing you don't understand is that pharma sales reps don't sell directly to patients. It's a highly regulated industry. Didn't mean it literally.. What I meant was not go to patient's house and sell it. Work with a small number of Drs (after looking at the trend from the last 2-3 years) in a very limited area, and when a patient gets a prescription, work with them to get insurance cleared, and then ship them the product directly (which Mike said he is planning to do now?). No idea this is legal or not. I'm just expressing my thoughts. Why are these guys repeating the same thing forever? They could try to educate Drs all over the country slowly provided they have 2/3 years of cash. When they barely have a few months of cash, why look at the whole country? Work in a city/county/zipcode. 9% of US population has diabetes. LA population is 4 million ==> 360,000 diabetes people. Assuming 1% are candidates for Afrezza == 36,000. If we could get 36,000 scripts from just LA, wouldn't it be awesome? Hypothetical. Again, I'm not saying MNKD should do exactly this.. Of course, I'm not in this industry, and I know next to nothing in this industry. I just invested in this looking at the drug. I don't know everything about everything. I too think it may be a good idea to work with a limited amount of physicians per state, and have the prescribing physician list be meaningful.
Regarding LA. Vdex is there. Vdex needs to have afrezza advertised.
|
|
|
|
Post by akemp3000 on Apr 21, 2017 17:13:02 GMT -5
A couple of things need to be remembered as we look at the current situation with, as you say, no emotion: 1) Afrezza is a paradigm changing solution for diabetics with no prandial equal and 2) BPs including Sanofi and others damn well know this. This is an existing mega billion dollar global industry at stake. There are a lot of possibilities going forward, some good, some bad. The idea that MNKD may go bankrupt and Afrezza will be tucked away forever is NOT going to happen. The efficacy of Afrezza is already entrenched in the diabetic world even if it's currently at a small niche. Something significant is going to happen with Afrezza. We just don't know who is going to own and manage it.
|
|
|
|
Post by nadathing on Apr 21, 2017 17:28:08 GMT -5
Question: Could MannKind go bankrupt? As hard as it is for me to say this, it is possible that MannKind could go bankrupt. They need cash to operate. I just don't see where it will be coming from for the next year. Question: Does Afrezza work? Your damn right it does. It's a life changing treatment for diabetes. It's a shame that the short buzzards don't give a damn about people with diabetes. There is a universal justice that will one day repay one way or another those that hurt others or unfairly profit off of another. Question: Would I still recommend Afrezza to PWD? Absolutely. To anyone that will listen. Question: If MannKind goes bankrupt, will I blame management or the BOD? Maybe a little. But it was just not possible to foresee all of the hurdles that MannKind would face. In the end, the thing that surprises me most, is when the diabetes world actually gets a gift like Afrezza, they are so slow to recognize it, that they potentially ensure its demise. Does Afrezza work? Not for many users. If it did, they would be refilling Scripps. If it work that well, doctors would be best to be prescribing it. Claiming that it is about the cost is ridiculous. People do not fill scripts they cannot afford. They don't refill, because they don't have success |
|
|
|
Post by dreamboatcruise on Apr 21, 2017 17:45:51 GMT -5
One thing you don't understand is that pharma sales reps don't sell directly to patients. It's a highly regulated industry. Didn't mean it literally.. What I meant was not go to patient's house and sell it. Work with a small number of Drs (after looking at the trend from the last 2-3 years) in a very limited area, and when a patient gets a prescription, work with them to get insurance cleared, and then ship them the product directly (which Mike said he is planning to do now?). No idea this is legal or not. I'm just expressing my thoughts. Why are these guys repeating the same thing forever? They could try to educate Drs all over the country slowly provided they have 2/3 years of cash. When they barely have a few months of cash, why look at the whole country? Work in a city/county/zipcode. 9% of US population has diabetes. LA population is 4 million ==> 360,000 diabetes people. Assuming 1% are candidates for Afrezza == 36,000. If we could get 36,000 scripts from just LA, wouldn't it be awesome? Hypothetical. Again, I'm not saying MNKD should do exactly this.. Of course, I'm not in this industry, and I know next to nothing in this industry. I just invested in this looking at the drug. I don't know everything about everything. Mannkind does have a system set to help patients with insurance coverage. Better to have that done by staff in the headquarters focused exclusively on it. There might be some hoops in each state to get cleared to directly mail Afrezza, but the other constraint would be business agreements to cover that with all the different insurers. Most insurers use PBMs. The PBMs likely have deals with most insurers so that drug companies can't cut them out like you are suggesting. Might be doable in the long run to boost profits, but in my opinion wouldn't be a critical thing now. Better to stay on top of distribution channel and make sure pharmacies can get it quickly. One could speculate that as hesitant as it seems doctors are to prescribe Afrezza, focusing on a small geographic area might simply yield too little. I think you are assuming that with enough attention from a sales rep most doctors' minds could be swayed. In reality we know that some doctors won't even talk to sales reps, and many others probably aren't going to change their prescribing practices based on a salesperson. I suspect Mannkind has been focusing on a relatively small number of doctors that have shown willingness to be early adopters (at least up until a few months ago), but unfortunately these doctors are spread out across the country. In my opinion, focusing could be very beneficial if they could get some big regional medical group such as Kaiser, with centralized decision making about drug use and coverage, to pick up Afrezza. Then cost effective regionally targeted advertising could be done. |
|
|
|
Post by cedafuntennis on Apr 21, 2017 17:57:25 GMT -5
While I agree with most you say, I strongly blame management for where we are now, not only in case of BK. Part of the reason why management gets such high salaries, golden parachutes and bonuses is a little thing called risk management. This is what project managers do as well. Mannkind should have raised a security blanked long ago when the price was at $10 not $0.20 cents, regardless of Sanofi or no Sanofi. Cash never goes bad. Should they have done that small thing, we would have NEVER been put in this position "of strength" now. At this point I see it as a lost war, hence the 8-K just filled to give management 1 more year of salaries. The only thing to save us and the patients would be a partnership and nothing looks forthcoming.
|
|
|
|
Post by dreamboatcruise on Apr 21, 2017 18:37:18 GMT -5
While I agree with most you say, I strongly blame management for where we are now, not only in case of BK. Part of the reason why management gets such high salaries, golden parachutes and bonuses is a little thing called risk management. This is what project managers do as well. Mannkind should have raised a security blanked long ago when the price was at $10 not $0.20 cents, regardless of Sanofi or no Sanofi. Cash never goes bad. Should they have done that small thing, we would have NEVER been put in this position "of strength" now. At this point I see it as a lost war, hence the 8-K just filled to give management 1 more year of salaries. The only thing to save us and the patients would be a partnership and nothing looks forthcoming. Fully agree with not raising cash sooner. Back when they did the deal with SNY and the stock went up, they should have quickly gone on the road with a presentation about aggressively reviving their pipeline and done a secondary to raise a significant amount of cash. Then behind the scenes they could have been more cautious, waiting to see if SNY would be successful. Heck, in hindsight it should have been done in early 2016 at $1.50 after they should have known what battle they were facing, or even after the bump related to SNY settlement in Nov at around $0.60. Now we are at $0.185 pre split equivalent. It does appear that they have significantly misjudged the difficulty they faced. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 21, 2017 19:01:43 GMT -5
A couple of things need to be remembered as we look at the current situation with, as you say, no emotion: 1) Afrezza is a paradigm changing solution for diabetics with no prandial equal and 2) BPs including Sanofi and others damn well know this. This is an existing mega billion dollar global industry at stake. There are a lot of possibilities going forward, some good, some bad. The idea that MNKD may go bankrupt and Afrezza will be tucked away forever is NOT going to happen. The efficacy of Afrezza is already entrenched in the diabetic world even if it's currently at a small niche. Something significant is going to happen with Afrezza. We just don't know who is going to own and manage it. 1)That is your opinion. There is no science to back that up 2) Your opinion once again. Do you realize how many cash strong pharmas that are dying for new innovation would love a drug like AFrezza |
|
|
|
Post by sla55 on Apr 21, 2017 19:10:18 GMT -5
What many of you fail recognize in my "Schwab rates Mannkind a "B" is the Jewish Cabal at work here. You need to look at all of the connections between the Jewish players at work here. I named all of them. Just look them up on Linked In and see who they are connected to. Do your homework. They immediately try to paint Flynn as a good guy white knight in response to my post on Schwab changing its rating from F to B?  . Originally they thought inhaled insulin would be a blockbuster. Now it's a bust. What many of you don't realize is the bot response at work to steal your money. Doctors don't think the marginal benefit of Afrezza is worth the risk! I lost a lot of money on the Mannkind hype. I suggest you reconsider your reasons for investing your hard-earned money in the hype. It is over! No money left to save the company. Careful people. This guy has been saying the same thing in 4 different threads so far. mnkd.proboards.com/thread/7612/brief-james-flynn?page=2 |
|
|
|
Post by liane on Apr 21, 2017 19:14:23 GMT -5
sla55 - it's been taken care of.
|
|
|
|
Post by sla55 on Apr 21, 2017 19:15:31 GMT -5
sla55 - it's been taken care of. Thanks Liane.  |
|
|
|
Post by kc on Apr 22, 2017 5:28:35 GMT -5
sla55 - it's been taken care of. Wow! I feel much better. I made a comment and statement that was off-base about a fellow member Peppy as it was buried in her quoted statement. Thank you liane for correcting and removing The offensive statement |
|
. Originally they thought inhaled insulin would be a blockbuster. Now it's a bust. What many of you don't realize is the bot response at work to steal your money. Doctors don't think the marginal benefit of Afrezza is worth the risk! I lost a lot of money on the Mannkind hype. I suggest you reconsider your reasons for investing your hard-earned money in the hype. It is over! No money left to save the company. 
